X-Therma

Executive Summary

X-Therma is addressing a critical bottleneck in regenerative medicine and cell therapy: the limited viability of organs, cells, and tissues during storage and transport. Current preservation methods rely on toxic cryoprotectants like DMSO, which cause cellular damage and restrict storage time to hours. X-Therma's platform, inspired by natural antifreeze proteins, enables DMSO-free biopreservation that dramatically extends the viable shelf life of biological materials. This technology has the potential to transform transplantation logistics, reduce organ discard rates, and make cell therapies truly 'off-the-shelf' treatments. Founded in 2016 and based in Vienna, the company is advancing its platform through preclinical studies and strategic collaborations. By overcoming the time, toxicity, and logistics constraints of existing methods, X-Therma's solution could unlock the full potential of living medicines. The company's approach is particularly relevant for cell therapies, where product stability is a major hurdle to scalability and patient access. With a strong patent portfolio and growing interest from the transplant and biopharma industries, X-Therma is well-positioned to become a key enabler in the cell and organ therapy ecosystem. The company is actively pursuing funding and partnerships to accelerate development toward clinical and commercial applications.

Upcoming Catalysts (preview)

• Q4 2026Series A financing to advance biopreservation platform70% success
• Q2 2027Initial proof-of-concept data for organ preservation75% success
• H1 2027Strategic collaboration with a regenerative medicine company60% success